Corporate Digest: General Motors delisting and STMicroelectronics share buyback
Companies released reports on listing changes, stock repurchases, shareholder meeting decisions, and operations. Below is a summary of key corporate events.

CAH Health Care · 3 analyses · 5 expectations tracked
Cardinal Health reported $67.5B in revenue (+5.5% YoY), compared with a +7.2% median across covered Health Care peers. Insider tracks 5 open management expectations for this company.
Companies released reports on listing changes, stock repurchases, shareholder meeting decisions, and operations. Below is a summary of key corporate events.
Cardinal Health reported first-quarter fiscal 2027 revenue of $67.5 billion, a 5.5% increase year-over-year. The quarter ended September 30, 2026.
On Oct. 1, 2026, Cardinal Health signed a binding letter of intent to extend its pharmaceutical distribution agreement with CVS Health to June 30, 2032, while reaffirming its fiscal 2027 non‑GAAP earnings per share (EPS) outlook of $12.40‑$12.60.
CARDINAL HEALTH INC: 12 recorded developments from 3 official sources in 2026-10.
Monthly records are drafted by AI from each month’s checked filings and official sources (in English, as extracted), with every line linked to its source; storylines group related developments across analyses using vector embeddings (Amazon Titan Text Embeddings V2). Provisional context, not investment advice.
From the 10-Q for the period ended September 30, 2026, filed November 5, 2026. SEC
| Latest | Earlier | Change | |
|---|---|---|---|
| Revenue quarter | $67.5B | $64B | +5.5% |
| Operating income quarter | $753M | $668M | +12.7% |
| Net income quarter | $554M | $450M | +23.1% |
| Diluted EPS quarter | $2.38 | $1.88 | +26.6% |
| Dividends per share quarter | $0.52 | $0.51 | +1.0% |
| Operating cash flow quarter | $1.4B | $973M | +43.7% |
| Cash and cash equivalents balance | $5.3B | $4.9B | +8.4% |
As the company tagged them in its filing (SEC XBRL). Quarter and year figures are compared with the same period a year earlier, balances with the previous balance sheet. Download CSV
Revenue by quarter, $B
How this company compares with 36 covered companies in Health Care (median revenue change +7.2% YoY), from archived SEC XBRL filings.
| Company | Latest revenue | Revenue YoY | Operating margin |
|---|---|---|---|
| Cardinal Health Inc CAH | $67.5B | +5.5% | 1.1% |
| Unitedhealth Group Inc UNH | $113B | -0.4% | 5.8% |
| Mckesson Corp MCK | $111B | +7.6% | 1.4% |
| CVS Health Corp CVS | $108B | +5.4% | 3.3% |
| Cigna Group CI | $73.7B | +5.6% | 3.3% |
| Elevance Health, Inc. ELV | $51.4B | +1.4% | 2.5% |
| Johnson & Johnson JNJ | $25.4B | +5.9% | — |
Latest reported period per company from SEC CompanyFacts (XBRL). Fiscal calendars differ across companies.
Growth rates for fiscal year 2027 guidance are based upon adjusted fiscal year 2026 non-GAAP diluted EPS of $10.95, excluding the fiscal year 2026 benefit from IEEPA tariff refund.
Not yet checked against later reports.
Raised fiscal year 2027 guidance for non-GAAP diluted EPS to $12.80 to $13.00.
Not yet checked against later reports.
Anticipates completing the acquisition of AdaptHealth’s Diabetes Health business.
Not yet checked against later reports.
The Company reaffirmed its previously issued fiscal year 2027 non-GAAP earnings per share (EPS) guidance range of $12.40 to $12.60 and its long-term non-GAAP EPS growth range guidance of 12% to 14%.
Not yet checked against later reports.
In connection with the renewal, Cardinal Health has reaffirmed its fiscal year 2027 non-GAAP EPS guidance of 13% to 15% growth1 ($12.40 to $12.60) and its long-term non-GAAP EPS growth rate guidance of 12% to 14%.
Not yet checked against later reports.
What management said to expect (targets, plans, forecasts) in the company's own documents (in English, as extracted), with the date and the period it named. Assessments are written by AI from the company's later reports: provisional, not checked by an editor, and a consistent later report is not proof. An editor's decision replaces them.
Filings about how the company is run: auditor changes, restatements, leadership changes, late filings, delistings, Schedule 13D stakes and SEC comment letters, newest first.
| Date | Event | Filing |
|---|---|---|
| August 5, 2026 | Director or officer departure or appointment (8-K item 5.02) | 8-K |
As filed with the SEC, read by code. A comment letter is part of the SEC staff’s routine review and does not by itself mean a problem; item 5.02 covers appointments as well as departures; Form 25 may concern a bond or another class of securities.
| Fund | Shares | Value | Change in shares | Quarter |
|---|---|---|---|---|
| BlackRock | 25,571,751 | $5,689,714,580 | -3.5% | Q3 2026 |
| State Street | 12,049,674 | $2,681,052,465 | +0.7% | Q3 2026 |
| Wellington Management | 9,866,422 | $2,195,278,898 | -33.6% | Q3 2026 |
| Geode Capital Management | 6,454,511 | $1,430,568,319 | -0.3% | Q3 2026 |
| Norges Bank (Norway's sovereign fund) | 3,726,422 | $885,248,810 | — | Q2 2026 |
| Fidelity (FMR) | 1,837,270 | $408,792,727 | -11.1% | Q3 2026 |
| D. E. Shaw & Co. | 872,765 | $194,190,213 | +58.6% | Q3 2026 |
| Renaissance Technologies | 835,700 | $185,943,250 | +51.9% | Q3 2026 |
| Millennium Management | 694,396 | $154,503,110 | +172.6% | Q3 2026 |
| Citadel Advisors | 251,321 | $55,918,923 | +29.6% | Q3 2026 |
| Bridgewater Associates | 128,388 | $28,566,330 | -2.8% | Q3 2026 |
| Two Sigma Investments | 1,400 | $332,584 | -99.7% | Q2 2026 |
| T. Rowe Price | 1,442,680 | $320,998 | -35.7% | Q3 2026 |
From the quarterly 13F-HR holdings reports of the large funds we follow, as filed. Funds file up to 45 days after the quarter ends, so positions may have changed since. Change: against the same fund's previous quarter. Not a recommendation.